Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 311 to 320 of 660 total matches.
Extended-Release Minocycline (Solodyn) for Acne
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006 (Issue 1248)
mg, and those >200 pounds,
135 mg.
96
The Medical Letter • Volume 48 • Issue 1248 ...
The FDA has approved an extended-release formulation of minocycline (Solodyn - Medicis) for once-daily treatment of non-nodular moderate to severe acne.
A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
) is available over the
counter (OTC). The NSAID ibuprofen in a dose of 200
mg (Advil, and others) is FDA ...
The FDA has approved an oral, fixed-dose combination (Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium (Anaprox, and others) for acute treatment of migraine attacks.
Armodafinil (Nuvigil) for Wakefulness
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010 (Issue 1344)
Dosage1 Cost2
Armodafinil 50, 150, 250 mg 150 mg $349.20
Nuvigil tabs
(Cephalon)
Modafinil – 100, 200 ...
Armodafinil (Nuvigil – Cephalon), the R-enantiomer of the non-amphetamine stimulant modafinil (Provigil – Cephalon; Alertec – Shire in Canada), is being promoted directly to the public for treatment of excessive daytime sleepiness associated with shift work.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
with remdesivir
(200 mg on day 1 and 100 mg on days 2 and 3) or
placebo. Hospitalization related to COVID-19 ...
The IV antiviral drug remdesivir (Veklury – Gilead)
has been available for treatment of COVID-19 in
hospitalized patients since 2020. Now, the FDA has
approved remdesivir for treatment of mild to moderate
COVID-19 in outpatients ≥12 years old who weigh
≥40 kg and are at high risk for progression to severe
disease, including hospitalization or death; they
also issued an Emergency Use Authorization (EUA)
allowing its use in any other high-risk outpatient who
weighs ≥3.5 kg.
Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
Calcitonin
Calcitonin – generic 200 IU/spray (3.7 mL bottle) Not approved 200 IU intranasally
once/day ...
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e112-4 doi:10.58347/tml.2024.1706b | Show Introduction Hide Introduction
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
25, 50, 100, mg tabs; 150, 50 mg once/day 50-200 mg once/day 2.90
Zoloft (Pfizer) 200 mg caps; 20 ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
vials; 1, 2 g/50 mL bags
Fluoroquinolones
Ciprofloxacin – generic 200 mg/20 mL, 400 mg/40 mL vials ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
a 200-mg dose of
nirsevimab or the same dose of palivizumab in their
second RSV season; there were ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
Abrocitinib – Cibinqo (Pfizer) 50, 100, 200 mg tabs 100 mg PO once/day2 $5567.30
Baricitinib – Olumiant ...
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in patients ≥12
years old (weight ≥40 kg). Lebrikizumab is the third
subcutaneously injected human IgG4 monoclonal
antibody to be approved in the US for this indication.
Tralokinumab (Adbry), another IL-13 antagonist, is
also approved for use in patients ≥12 years old, and
dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is
approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81 doi:10.58347/tml.2024.1715b | Show Introduction Hide Introduction
Acesulfame - A New Artificial Sweeteners
The Medical Letter on Drugs and Therapeutics • Dec 16, 1988 (Issue 781)
is soluble in water and stable at
temperatures up to about 225° C. The sweetness of acesulfame is 200 times ...
Acesulfame potassium (Sunette - Hoechst), an oxathiazinondioxide, was recently approved by the US Food and Drug Administration (FDA) for use as a non-caloric table-top sweetener and as an ingredient in chewing gum, powdered beverages, gelatins and puddings. The other non-caloric artificial sweeteners available in the USA are saccharin (Sweet 'N Low; and others) and aspartame (NutraSweet; Equal) (Medical Letter, 24:1, 1982).